Bank Leumi and Israel Cancer Research Fund invite you to meet their leaders


Mark A. Israel, M.D. National Executive Director of ICRF discussing developments in cancer research in Israel
Read more



Avner Mendelson, President and Chief Executive Officer of Bank Leumi USA
Read more

Location and Time

Thursday May 3, 6:30PM
Bank Leumi, 350 Madison Avenue (between East 44th and East 45th Streets) 5th floor

Cocktails and Hors D’oeuvres Served


ICRF supporters respond to Ken Gabel ( or David Kweskin (
Leumi clients respond to Michael Zaremsky (

Speaker Bios

Avner Mendelson is President & CEO of Bank Leumi USA. Avner was appointed to this role in 2013 with a mandate to orchestrate a major strategic transformation of the organization. With a new management team, a focused business strategy, expanded products and services offering, and a complete revamp of the firm’s core technology system, the Bank’s revenues have grown by more than 50%, and profits have more than quadrupled in the past 4 years.

Most recently, Avner spearheaded a strategic investment in the Bank by Endicott Management Company and MSD Capital, L.P., a private investment firm that manages the assets of Michael Dell and his family, to assist in the Bank’s continued growth while adding value to the Leumi Group.

Avner has been with the Leumi Group since 2007, serving as Head of Group Strategy and International Operations, as well as Chief of Staff to the President and CEO. Prior to joining the Leumi Group, he was a Senior Consultant with McKinsey & Company in London. Avner also served in the Israeli Defense Forces.

Avner earned his bachelor’s degree in economics and international relations from The Hebrew University of Jerusalem and his MBA from the Wharton School of Business. He is actively involved with several non-profit organizations and serves on both the Northeast Regional Board and the Board of Regents for the American Friends of The Hebrew University and the Board of Directors of the Shefa School.


Dr. Mark A. Israel, a pediatric oncologist, translational scientist and a nationally recognized leader in cancer research, came to the Israel Cancer Research Fund (ICRF), in January 2018 as National Executive Director.

Dr. Israel joins ICRF from the Geisel School of Medicine at Dartmouth College, where he is a professor in the Department of Pediatrics, Medicine, and Molecular and Systems Biology. From 2001 to 2016, Dr. Israel served as the Director of Dartmouth’s National Cancer Institute-designated Comprehensive Cancer Center, the Norris Cotton Cancer Center, where he was responsible for delivering comprehensive clinical care to more than 30,000 patients annually. Dr. Israel organized Dartmouth’s cancer research efforts with an annual budget in excess of $50 million and oversaw the cancer center’s development efforts, raising as much as $10 million annually.

For the last 12 years, Dr. Israel has been a volunteer member of the ICRF’s Scientific Review Panel and the chair of the panel that evaluates translational cancer research proposals.

“Cancer research has never been more exciting or promising – and that is particularly true in Israel,” Dr. Israel noted on accepting this position. “Israeli science knows no bounds. ICRF provides a singular opportunity to help build more recognition and support for the world-class cancer research of Israeli scientists, and to arm and empower its finest practitioners with the resources necessary to change the world.”

Before joining Dartmouth in 2001, Dr. Israel was Professor in the Departments of Neurological Surgery and Pediatrics at the University of California-San Francisco (UCSF) where he also directed the Preuss Laboratory of Molecular Neuro-Oncology. At UCSF, he held the Kathleen M. Plant Distinguished Professorship. Earlier in his career, Dr. Israel held several positions at the National Cancer Institute, including Head of the Molecular Genetics Section of the Pediatrics Branch.

Dr. Israel has served on numerous boards, editorial boards, and advisory committees, including several U.S. National Cancer Institute-designated Comprehensive Cancer Center scientific advisory boards. He is the recipient of several awards and honors, including the C. Everett Koop Courage Award, the Farber Award from the American Association of Neurological Surgeons, the Heinz Karger Memorial Foundation Prize, and the U.S. Public Health Service Commendations Medal, among others.

Dr. Israel is also an elected Fellow of the American Association for the Advancement of Science. He holds three patents and is author or co-author of hundreds of scholarly papers.